KORU Medical Systems

KRMD · NASDAQ

$3.04+$0.02 (+0.66%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.02

KRMD analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $6.38 (+109.7% upside)

Low: $5.05
Now: $3.04
High: $8.40

Upgrades and downgrades

The latest rating actions, newest first

KRMD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Canaccord Genuity	Mar 13, 2026	Maintains	Buy	$6.00	38%
B. Riley Securities	Mar 13, 2026	Maintains	Buy	$7.00 → $8.00	23%
Lake Street	Dec 22, 2025	Maintains	Buy	$6.00 → $8.00	36%
Canaccord Genuity	Dec 17, 2025	Maintains	Buy	$5.00 → $6.00	38%

The case for and against

Updated Oct 22, 2025

Bull case

KORU Medical Systems Inc. demonstrated strong financial performance in the first quarter, achieving revenue of $9.6 million, representing a year-over-year increase of 17.5%, fueled by substantial growth in both U.S. and international markets at 16% and 36%, respectively. Additionally, the company's gross margin percentage expanded by 50 basis points to 62.8%, indicating operational efficiency amid a shifting geographic mix. Management's confidence is further underscored by their decision to raise the 2025 revenue guidance by $0.5 million and plans to submit for approval two commercialized drugs related to the Freedom Infusion System later this year.

Bear case

KORU Medical Systems reported an operating loss of $1.2 million, indicating ongoing financial challenges despite its focus on the high-demand market of infusion devices for chronic illnesses. The company’s performance metrics revealed operational efficiencies that did not meet expectations, reflecting a potential misalignment with industry standards. This financial strain raises concerns about the company's ability to scale effectively within a competitive medical device sector.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.